Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/93834
Title: | GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure | Authors: | Fonseca, Nuno A. Gregório, Ana C. Mendes, Vera M. Lopes, Rui Abreu, Teresa Gonçalves, Nélio Manadas, Bruno Lacerda, Manuela Figueiredo, Paulo Pereira, Marta Gaspar, Manuela Colelli, Fabiana Pesce, Daniela Signorino, Giacomo Focareta, Laura Fucci, Alessandra Cardile, Francesco Pisano, Claudio Cruz, Tony Almeida, Luís Moura, Vera Simões, Sérgio Moreira, João N. |
Keywords: | Nucleolin; Targeted-drug delivery; Mesothelioma; Breast cancer; Nucleolin-overexpressing cancers | Issue Date: | Apr-2021 | Publisher: | Elsevier | Project: | POCI-01-0145-FEDER-016390 (acronym: CANCEL STEM) Healthy Aging 2020: CENTRO-01-0145-FEDER-000012 info:eu-repo/grantAgreement/EC/FP7/234811/EU/EUROpean network of trans-national collaborative RTD in the field of NANOMEDicine |
Serial title, monograph or event: | Nano Today | Volume: | 37 | Abstract: | Patients with breast or ovarian cancer have not benefited from improved efficacy with pegylated liposomal doxorubicin relative to free drug, likely due to the limited extent of the enhanced permeability and retention (EPR) effect, further compromising drug bioavailability in the tumor. Herein it is hypothesized that targeting nucleolin overexpressed in tumor endothelial cells (readily accessible from the vascular compartment), besides cancer cells, with PEGASEMP (doxorubicin hydrochloride in a lipid-based pegylated nanoparticle functionalized with a 31-aminoacid peptide targeting nucleolin), lessens the dependence on high systemic exposures and EPR effect for successful tumor targeting. This strategy has resulted in improved intracellular tumor bioavailability of doxorubicin, at low systemic exposure, associated with a safe toxicological profile. Levels of cell surface nucleolin dictated the antitumor activity of PEGASEMP against nucleolin-overexpressing solid tumors of diverse histological origin, evidencing a significant growth inhibition of malignant mesothelioma over the standard of care. Those observations were paralleled by an impairment of the nucleolin-positive vasculature and downregulation of typically overexpressed genes. Patient stratification based on nucleolin mRNA expression correlated with prognosis and enabled identification of breast and mesothelioma tumors that may potentially benefit from PEGASEMP. Overall, a novel principle of drug delivery is presented with potential therapeutic impact across nucleolin-overexpressing human cancers. | URI: | https://hdl.handle.net/10316/93834 | ISSN: | 17480132 | DOI: | 10.1016/j.nantod.2021.101095 | Rights: | embargoedAccess |
Appears in Collections: | I&D CNC - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S1748013221000207-main.pdf | 15.01 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
10
checked on Nov 11, 2022
WEB OF SCIENCETM
Citations
12
checked on May 2, 2023
Page view(s)
257
checked on Aug 28, 2024
Download(s)
117
checked on Aug 28, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License